The global multiple assay market accounted for USD 2.36 billion in 2023 and is expected to reach at USD 10.75 billion by 2034 with a CAGR of 14.78% during the forecast period 2024-2034. Increasing prevalence of both chronic & infectious diseases, growing recognition of the significant benefits of multiplex assays compared to singleplex & traditional assays, rising utilization of multiplex assays in companion diagnostics, surge in awareness of the importance of early disease detection, a heightened demand for innovative diagnostic tools, the necessity for high-throughput assays & automated systems, and growing launch of new multiple assay products are some of the key factors boosting the market growth.
A multiplex assay is a method used to simultaneously detect and quantify various analytes, including growth factors, chemokines, biomolecules, cytokines, and proteins, among others. This technique finds widespread application in mutation analysis, linkage analysis, pathogen identification, forensic studies, and gene detection analysis, among other uses. Hence, growing launch of new multiple assay products is predicted to boost the market growth during the forecast period. For instance, in November 2022, Sentinel Diagnostics, headquartered in Milan, Italy, introduced SentiNat 200, a sample-to-result system that is fully automated, along with Stat-Nat SN200 Real-Time PCR assays. These assays are capable of quantitatively detecting 10 different viruses.
By product, consumables was the highest revenue-grossing segment in the global multiple assay market in 2023 owing to the increase in the frequency of consumable purchases and rise in the number of diagnostic tests being conducted. Additionally, software is predicted to grow at the fastest CAGR during the forecast period owing to the superior efficiency of software and increasing number of product launches. For instance, in August 2022, Bio-Techne Corporation has introduced Quantist Luminex data analysis software, designed to assist researchers in deriving valuable insights from intricate data sets. Additionally, instruments is predicted to grow at the fastest CAGR during the forecast period owing to the adoption of instruments and accessories is on the rise, alongside an increase in the number of R&D labs utilizing these instruments and accessories.
By type, protein multiplex assay was the highest revenue-grossing segment in the global multiple assay market in 2023 owing to the growing emphasis on proteomics studies for biomarker research and clinical diagnostics and increasing utilization of protein multiplex assays in proteomics research. Additionally, nucleic acid assay is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of chronic & infectious diseases and rising new product launches. For instance, in July 2022, Bio-Rad Laboratories has introduced the CFX Opus Deepwell Real-Time PCR Detection System, aimed at assisting researchers in creating assays for nucleic acid detection. This system enables the simultaneous multiplexing of up to five targets and is compatible with fluorescence resonance energy transfer applications.
By technology, flow cytometry was the highest revenue-grossing segment in the global multiple assay market in 2023 owing to the rising technological advancements, surge in introduction of novel flow cytometers, and increasing launch new products. For instance, in August 2022, Bio-Rad Laboratories, Inc. has broadened its selection of StarBright Violet and UltraViolet dyes for multiplexed flow cytometry, offering researchers stable and specific options tailored to key immunophenotyping targets. These dyes support the creation of multiplex flow cytometry panels in immunology research. Additionally, multiplex real-time PCR is predicted to grow at the fastest CAGR during the forecast years. Multiplex real-time PCR is an adapted form of traditional PCR, amplifying multiple target sequences using different sets of primers within one PCR mixture. It regulates internal amplification to improve the precision of negative PCR outcomes. Moreover, this method facilitates the identification of diverse pathogens in a single reaction. These benefits are expected to enhance its utilization in clinical diagnostics, consequently driving industry expansion in the foreseeable future.
By application, research & development was the highest revenue-grossing segment in the global multiple assay market in 2023 owing to the rising need for multiplex assays in drug discovery, and increase in research & development endeavors. Additionally, clinical diagnostics is predicted to grow at the fastest CAGR during the forecast period owing to the growing prevalence of chronic diseases, including autoimmune diseases, infectious diseases, cancer, & cardiovascular diseases (CVDs) and increasing influx of new products being introduced to address these conditions. For instance, in April 2022, Bruker Corporation introduced an innovative LiquidArray multiplex PCR assay capable of detecting seven key pathogens responsible for Sexually Transmitted Infections (STIs).
By end-user, pharmaceutical & biotechnology companies was the highest revenue-grossing segment in the global multiple assay market in 2023 owing to the pharmaceutical & biotechnology partnerships & collaborations are on the rise, aimed at enhancing multiplexing capabilities. For instance, in August 2022, BD (Becton, Dickinson and Company) and Labcorp, a prominent global life sciences company, have formed a collaborative agreement. This partnership establishes a framework for the development, manufacturing, marketing, and commercialization of flow cytometry-based companion diagnostics (CDx). These diagnostics are designed to pair patients with transformative treatments for cancer and other illnesses. Additionally, hospitals & diagnostic laboratories is predicted to grow at the fastest CAGR during the forecast period owing to the increasing need for prompt and precise diagnosis of various chronic diseases and growing prevalence of respiratory disorders.
North America region is anticipated for the highest revenue share during the forecast period owing to the expanding research & development efforts to create innovative diagnosis & treatment options, rising incidence of chronic conditions such as stroke & cancer, surge in government funding for the discovery of new biomarkers, and growing introduction of new assay kits. For instance, in May 2022, InDevR, Inc. introduced the VaxArray Pneumococcal Assay kit, a multiplex tool designed for the quick and precise evaluation of pneumococcal vaccines throughout all manufacturing phases, including multivalent drug products. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising hospital count, increasing research & development sector, surge in investments by emerging players, rising incidence of cancer, and growing trend of collaborations among market players to introduce innovative products.. For instance, in May 2022, Cipla Limited has revealed the launch of the 'RT-Direct' multiplex COVID-19 RT PCR Test kit in India, in collaboration with Genes2Me Pvt. Ltd. This move signifies Cipla's expansion of its diagnostics portfolio to introduce more sophisticated and innovative products.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
A multiplex assay is a method used to simultaneously detect and quantify various analytes, including growth factors, chemokines, biomolecules, cytokines, and proteins, among others. This technique finds widespread application in mutation analysis, linkage analysis, pathogen identification, forensic studies, and gene detection analysis, among other uses. Hence, growing launch of new multiple assay products is predicted to boost the market growth during the forecast period. For instance, in November 2022, Sentinel Diagnostics, headquartered in Milan, Italy, introduced SentiNat 200, a sample-to-result system that is fully automated, along with Stat-Nat SN200 Real-Time PCR assays. These assays are capable of quantitatively detecting 10 different viruses.
By product, consumables was the highest revenue-grossing segment in the global multiple assay market in 2023 owing to the increase in the frequency of consumable purchases and rise in the number of diagnostic tests being conducted. Additionally, software is predicted to grow at the fastest CAGR during the forecast period owing to the superior efficiency of software and increasing number of product launches. For instance, in August 2022, Bio-Techne Corporation has introduced Quantist Luminex data analysis software, designed to assist researchers in deriving valuable insights from intricate data sets. Additionally, instruments is predicted to grow at the fastest CAGR during the forecast period owing to the adoption of instruments and accessories is on the rise, alongside an increase in the number of R&D labs utilizing these instruments and accessories.
By type, protein multiplex assay was the highest revenue-grossing segment in the global multiple assay market in 2023 owing to the growing emphasis on proteomics studies for biomarker research and clinical diagnostics and increasing utilization of protein multiplex assays in proteomics research. Additionally, nucleic acid assay is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of chronic & infectious diseases and rising new product launches. For instance, in July 2022, Bio-Rad Laboratories has introduced the CFX Opus Deepwell Real-Time PCR Detection System, aimed at assisting researchers in creating assays for nucleic acid detection. This system enables the simultaneous multiplexing of up to five targets and is compatible with fluorescence resonance energy transfer applications.
By technology, flow cytometry was the highest revenue-grossing segment in the global multiple assay market in 2023 owing to the rising technological advancements, surge in introduction of novel flow cytometers, and increasing launch new products. For instance, in August 2022, Bio-Rad Laboratories, Inc. has broadened its selection of StarBright Violet and UltraViolet dyes for multiplexed flow cytometry, offering researchers stable and specific options tailored to key immunophenotyping targets. These dyes support the creation of multiplex flow cytometry panels in immunology research. Additionally, multiplex real-time PCR is predicted to grow at the fastest CAGR during the forecast years. Multiplex real-time PCR is an adapted form of traditional PCR, amplifying multiple target sequences using different sets of primers within one PCR mixture. It regulates internal amplification to improve the precision of negative PCR outcomes. Moreover, this method facilitates the identification of diverse pathogens in a single reaction. These benefits are expected to enhance its utilization in clinical diagnostics, consequently driving industry expansion in the foreseeable future.
By application, research & development was the highest revenue-grossing segment in the global multiple assay market in 2023 owing to the rising need for multiplex assays in drug discovery, and increase in research & development endeavors. Additionally, clinical diagnostics is predicted to grow at the fastest CAGR during the forecast period owing to the growing prevalence of chronic diseases, including autoimmune diseases, infectious diseases, cancer, & cardiovascular diseases (CVDs) and increasing influx of new products being introduced to address these conditions. For instance, in April 2022, Bruker Corporation introduced an innovative LiquidArray multiplex PCR assay capable of detecting seven key pathogens responsible for Sexually Transmitted Infections (STIs).
By end-user, pharmaceutical & biotechnology companies was the highest revenue-grossing segment in the global multiple assay market in 2023 owing to the pharmaceutical & biotechnology partnerships & collaborations are on the rise, aimed at enhancing multiplexing capabilities. For instance, in August 2022, BD (Becton, Dickinson and Company) and Labcorp, a prominent global life sciences company, have formed a collaborative agreement. This partnership establishes a framework for the development, manufacturing, marketing, and commercialization of flow cytometry-based companion diagnostics (CDx). These diagnostics are designed to pair patients with transformative treatments for cancer and other illnesses. Additionally, hospitals & diagnostic laboratories is predicted to grow at the fastest CAGR during the forecast period owing to the increasing need for prompt and precise diagnosis of various chronic diseases and growing prevalence of respiratory disorders.
North America region is anticipated for the highest revenue share during the forecast period owing to the expanding research & development efforts to create innovative diagnosis & treatment options, rising incidence of chronic conditions such as stroke & cancer, surge in government funding for the discovery of new biomarkers, and growing introduction of new assay kits. For instance, in May 2022, InDevR, Inc. introduced the VaxArray Pneumococcal Assay kit, a multiplex tool designed for the quick and precise evaluation of pneumococcal vaccines throughout all manufacturing phases, including multivalent drug products. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising hospital count, increasing research & development sector, surge in investments by emerging players, rising incidence of cancer, and growing trend of collaborations among market players to introduce innovative products.. For instance, in May 2022, Cipla Limited has revealed the launch of the 'RT-Direct' multiplex COVID-19 RT PCR Test kit in India, in collaboration with Genes2Me Pvt. Ltd. This move signifies Cipla's expansion of its diagnostics portfolio to introduce more sophisticated and innovative products.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Type, Technology, Application, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Multiple Assay Market Report 2023 - 2034
Multiple Assay Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Software
- Instruments
- Consumables
Multiple Assay Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Cell-based Multiplex Assays
- Nucleic Acid Multiplex Assays
- Bead-based Protein Assays
- Planar Protein Assays
- Protein Multiplex Assays
- Bead-based Protein Assays
- Planar Protein Assays
Multiple Assay Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Luminescence
- Flow Cytometry
- Multiplex Real-time PCR
- Fluorescence Detection
- Other Technologies
Multiple Assay Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Clinical Diagnostics
- Metabolism & Endocrinology Disorders
- Nervous System Disorders
- Cardiovascular Diseases
- Autoimmune Diseases
- Infectious Diseases
- Cancer
- Other Diseases
- Research & Development
- Biomarker Discovery & Validation
- Drug Discovery & Development
Multiple Assay Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Research & Academic Institutes
- Hospitals & Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Others
Multiple Assay Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Multiple Assay Market: Product Estimates & Trend Analysis
8. Multiple Assay Market: Type Estimates & Trend Analysis
9. Multiple Assay Market: Technology Estimates & Trend Analysis
10. Multiple Assay Market: Application Estimates & Trend Analysis
11. Multiple Assay Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Multiple Assay Market
14. Europe Global Multiple Assay Market
15. Asia Pacific Global Multiple Assay Market
16. Latin America Global Multiple Assay Market
17. MEA Global Multiple Assay Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Advanced Cell Diagnostics Inc.
- Assay Genie
- Seegene Inc.
- QIAGEN N.V.
- Promega Connections
- Luminex Corp.
- Bio-Rad Laboratories Inc.
- Abcam plc.
- Thermo Fisher Scientific
- Merck KGaA
- Perkin Elmer Inc.
- R&D Systems Inc.
